STARPHARMA HOLDINGS LIMITED - Announcements

0.00%

13.0¢

Market Cap $54.36M

Healthcare Biotechnology

Starpharma Holdings Limited is an Australia-based biotechnology company. The principal... Starpharma Holdings Limited is an Australia-based biotechnology company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its portfolio of dendrimer-based products includes three clinical-stage DEP (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products. It has developed a pipeline of novel DEP oncology products. Its clinical-stage assets, DEP SN38, DEP cabazitaxel, and DEP docetaxel, are dendrimer-based chemotherapeutic drugs. Additionally, it has a preclinical pipeline of DEP radiopharmaceuticals and DEP Antibody-Drug Conjugates (ADCs) in development. Its VIRALEZE Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products. More

Announcements

Filter Results

All Price Sensitive Only

SPL	Change in substantial holding		28/04/22	170.7KB	Share
SPL	Starpharma to present DEP at Boston ADC summit		27/04/22	224.42KB	Share
SPL	Dr Jeff Davies appointed as director and Appendix 3X		01/04/22	381.89KB	Share
SPL	VIRALEZE to relaunch in the UK	PRICE SENSITIVE	01/04/22	257.72KB	Share
SPL	Application for quotation of securities - SPL		17/03/22	26.23KB	Share
SPL	Response to media article		04/03/22	204.26KB	Share
SPL	SPL7013 in VIRALEZE virucidal against Omicron	PRICE SENSITIVE	01/03/22	333.51KB	Share
SPL	Dr Jeff Davies appointed as non-executive director		24/02/22	196.6KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	21/02/22	1016.82KB	Share
SPL	VIRALEZE distribution in Saudi Arabia - supplementary info		04/02/22	193.62KB	Share
SPL	Change in substantial holding		04/02/22	320.47KB	Share
SPL	VIRALEZE sales and distribution in Saudi Arabia and GCC	PRICE SENSITIVE	03/02/22	273.05KB	Share
SPL	Application for quotation of securities - SPL		01/02/22	26.23KB	Share
SPL	Application for quotation of securities - SPL		01/02/22	26.51KB	Share
SPL	Notification of cessation of securities - SPL		01/02/22	21.47KB	Share
SPL	Quarterly Cashflow and Activities Report	PRICE SENSITIVE	28/01/22	693.79KB	Share
SPL	Starpharma receives $7.7M R&D tax incentive refund	PRICE SENSITIVE	20/01/22	215.29KB	Share
SPL	Notification of cessation of securities - SPL		23/12/21	21.47KB	Share
SPL	Shareholder Newsletter		16/12/21	984.28KB	Share
SPL	VIRALEZE antiviral nasal spray registered in Saudi Arabia		14/12/21	238.22KB	Share
SPL	VIRALEZE successfully launched in Vietnam	PRICE SENSITIVE	13/12/21	214.71KB	Share
SPL	US Biopharma DEP Research Agreement - Additional Information		08/12/21	199.56KB	Share
SPL	Starpharma signs DEP Research Agreement with US Biopharma Co	PRICE SENSITIVE	07/12/21	201.34KB	Share
SPL	Change in Director's Interest Notice - J Fairley		03/12/21	190.99KB	Share
SPL	Notification regarding unquoted securities - SPL		03/12/21	25.01KB	Share
SPL	VIRALEZE distribution agreement and launch in Vietnam	PRICE SENSITIVE	03/12/21	223.84KB	Share
SPL	VIRALEZE registered in Vietnam with launch this week	PRICE SENSITIVE	01/12/21	213.23KB	Share
SPL	AGM Results		30/11/21	212.4KB	Share
SPL	AGM Chairman address and CEO presentation	PRICE SENSITIVE	30/11/21	9.34MB	Share
SPL	Positive DEP phase 2 interim results in prostate cancer	PRICE SENSITIVE	25/11/21	325.01KB	Share
SPL	Jobkeeper s323DB(1) notice		11/11/21	217.03KB	Share
SPL	Starpharma to present at Bell Potter Healthcare Conference		09/11/21	6.06MB	Share
SPL	Application for quotation of securities - SPL		01/11/21	26.23KB	Share
SPL	Notice of Annual General Meeting/Proxy Form		29/10/21	2.04MB	Share
SPL	Quarterly Cashflow and Activities Report	PRICE SENSITIVE	29/10/21	520.01KB	Share
SPL	Starpharma to present DEP at US Drug Delivery Conference		28/10/21	207.37KB	Share
SPL	VIRALEZE distribution and supply to Vietnam	PRICE SENSITIVE	26/10/21	223.97KB	Share
SPL	Notification regarding unquoted securities - SPL		25/10/21	26.46KB	Share
SPL	VIRALEZE ADMENTA agreement - supplementary information		12/10/21	203.32KB	Share
SPL	VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy	PRICE SENSITIVE	08/10/21	434.53KB	Share
SPL	Change in Director's Interest Notice - J Fairley		01/10/21	191.8KB	Share
SPL	Notification of cessation of securities - SPL		01/10/21	21.51KB	Share
SPL	2021 Annual General Meeting		01/10/21	194.43KB	Share
SPL	US patent issued for DEP cabazitaxel nanoparticle		15/09/21	223.41KB	Share
SPL	Application for quotation of securities - SPL		13/09/21	26.23KB	Share
SPL	Change in Director's Interest Notice - Z Peach		31/08/21	170.47KB	Share
SPL	Change in Director's Interest Notice - J Fairley		30/08/21	189.4KB	Share
SPL	Change in Director's Interest Notice - R Thomas		27/08/21	171.95KB	Share
SPL	Change in Director's Interest Notice - L Cheng		27/08/21	170.49KB	Share
SPL	Appendix 4G - Corporate Governance Statement		26/08/21	401.05KB	Share
SPL	Starpharma annual report and full year financial results	PRICE SENSITIVE	26/08/21	4.97MB	Share
SPL	VIRALEZE Protects Against SARS-CoV-2 in Challenge Model	PRICE SENSITIVE	23/08/21	346.96KB	Share
SPL	VIRALEZE well tolerated in multiple dose clinical study	PRICE SENSITIVE	17/08/21	218.14KB	Share
SPL	Initial Director's Interest Notice		02/08/21	237.65KB	Share
SPL	Quarterly Cashflow and Activities Report	PRICE SENSITIVE	30/07/21	458.77KB	Share
SPL	Resignation of non-executive director		29/07/21	409.71KB	Share
SPL	Lynda Cheng appointed as non-executive director		28/07/21	194.8KB	Share
SPL	Starpharma to present DEP platform at CRS Annual Meeting		27/07/21	195.96KB	Share
SPL	VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant	PRICE SENSITIVE	27/07/21	293.54KB	Share
SPL	TGA infringement notices for alleged advertising		05/07/21	199.5KB	Share
SPL	Change in substantial holding		02/07/21	6.44MB	Share
SPL	Starpharma to present at Virtual Life Science Investor Forum		24/06/21	6.78MB	Share
SPL	VIRALEZE UK Update	PRICE SENSITIVE	21/06/21	189.86KB	Share
SPL	VIRALEZE SPL7013 virucidal against multiple COVID variants	PRICE SENSITIVE	18/06/21	489.28KB	Share
SPL	VIRALEZE antiviral nasal spray registered for sale in India	PRICE SENSITIVE	11/06/21	271.42KB	Share
SPL	VIRALEZE SPL7013 highly active in UK variant of coronavirus	PRICE SENSITIVE	01/06/21	506.94KB	Share
SPL	VIRALEZE partners with Harlequins in the UK		11/05/21	851.24KB	Share
SPL	VIRALEZE launches in Europe	PRICE SENSITIVE	06/05/21	218.14KB	Share
SPL	Shareholder Newsletter		28/04/21	1.13MB	Share
SPL	Quarterly Cashflow and Activities Report	PRICE SENSITIVE	27/04/21	296.53KB	Share
SPL	Appendix 2A		09/04/21	300.37KB	Share
SPL	VIRALEZE now launched by LloydsPharmacy in the UK		30/03/21	223.8KB	Share
SPL	VIRALEZE to be launched with LloydsPharmacy in the UK	PRICE SENSITIVE	25/03/21	240.28KB	Share
SPL	DEP HER2-lutetium outperforms in human breast cancer model	PRICE SENSITIVE	16/03/21	252.17KB	Share
SPL	SPL7013 active against other pandemic coronaviruses		03/03/21	417.63KB	Share
SPL	Interim Report and Half-Year Financial Results	PRICE SENSITIVE	25/02/21	1.36MB	Share
SPL	VIRALEZE antiviral nasal spray registered in Europe	PRICE SENSITIVE	23/02/21	225.86KB	Share
SPL	Starpharma signs DEP ADC Research Agreement with MSD	PRICE SENSITIVE	12/02/21	171.94KB	Share
SPL	AZD0466 clinical DEP program global expansion	PRICE SENSITIVE	09/02/21	58.71KB	Share
SPL	Change in substantial holding		03/02/21	5.18MB	Share
SPL	Quarterly Cashflow and Activities Report	PRICE SENSITIVE	29/01/21	102.2KB	Share
SPL	Appendix 2A		27/01/21	167.74KB	Share
SPL	Change in substantial holding		18/01/21	188.68KB	Share
SPL	Change in substantial holding		18/01/21	200.44KB	Share
SPL	Change in substantial holding		24/12/20	84.03KB	Share
SPL	VIRALEZE COVID-19 nasal spray study to commence in January	PRICE SENSITIVE	22/12/20	70.54KB	Share
SPL	Change in substantial holding		22/12/20	467.34KB	Share
SPL	VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21	PRICE SENSITIVE	10/12/20	112.23KB	Share
SPL	Change in Director's Interest Notice - J Fairley		24/11/20	75.25KB	Share
SPL	Appendix 3G		24/11/20	131.6KB	Share
SPL	Retirement of non-executive director Richard Hazleton		20/11/20	209.68KB	Share
SPL	2020 AGM Results		20/11/20	84KB	Share
SPL	AGM Chairman address and CEO presentation	PRICE SENSITIVE	20/11/20	3.8MB	Share
SPL	SPL7013 shows potent antiviral activity in RSV	PRICE SENSITIVE	19/11/20	94.96KB	Share
SPL	Appendix 3G		13/11/20	134.12KB	Share
SPL	Change in Director's Interest Notice - R Thomas		04/11/20	75.62KB	Share
SPL	Change in Director's Interest Notice - J Fairley		04/11/20	166.14KB	Share
SPL	Change in Director's Interest Notice - Peter Turvey		04/11/20	74.7KB	Share
SPL	Appendix 2A		04/11/20	169.13KB	Share
SPL	Appendix 2A		30/10/20	173KB	Share

SPL Change in substantial holding
28/04/22		170.7KB	Share
SPL Starpharma to present DEP at Boston ADC summit
27/04/22		224.42KB	Share
SPL Dr Jeff Davies appointed as director and Appendix 3X
01/04/22		381.89KB	Share
SPL VIRALEZE to relaunch in the UK
01/04/22	PRICE SENSITIVE	257.72KB	Share
SPL Application for quotation of securities - SPL
17/03/22		26.23KB	Share
SPL Response to media article
04/03/22		204.26KB	Share
SPL SPL7013 in VIRALEZE virucidal against Omicron
01/03/22	PRICE SENSITIVE	333.51KB	Share
SPL Dr Jeff Davies appointed as non-executive director
24/02/22		196.6KB	Share
SPL Interim Report and Half-Year Financial Results
21/02/22	PRICE SENSITIVE	1016.82KB	Share
SPL VIRALEZE distribution in Saudi Arabia - supplementary info
04/02/22		193.62KB	Share
SPL Change in substantial holding
04/02/22		320.47KB	Share
SPL VIRALEZE sales and distribution in Saudi Arabia and GCC
03/02/22	PRICE SENSITIVE	273.05KB	Share
SPL Application for quotation of securities - SPL
01/02/22		26.23KB	Share
SPL Application for quotation of securities - SPL
01/02/22		26.51KB	Share
SPL Notification of cessation of securities - SPL
01/02/22		21.47KB	Share
SPL Quarterly Cashflow and Activities Report
28/01/22	PRICE SENSITIVE	693.79KB	Share
SPL Starpharma receives $7.7M R&D tax incentive refund
20/01/22	PRICE SENSITIVE	215.29KB	Share
SPL Notification of cessation of securities - SPL
23/12/21		21.47KB	Share
SPL Shareholder Newsletter
16/12/21		984.28KB	Share
SPL VIRALEZE antiviral nasal spray registered in Saudi Arabia
14/12/21		238.22KB	Share
SPL VIRALEZE successfully launched in Vietnam
13/12/21	PRICE SENSITIVE	214.71KB	Share
SPL US Biopharma DEP Research Agreement - Additional Information
08/12/21		199.56KB	Share
SPL Starpharma signs DEP Research Agreement with US Biopharma Co
07/12/21	PRICE SENSITIVE	201.34KB	Share
SPL Change in Director's Interest Notice - J Fairley
03/12/21		190.99KB	Share
SPL Notification regarding unquoted securities - SPL
03/12/21		25.01KB	Share
SPL VIRALEZE distribution agreement and launch in Vietnam
03/12/21	PRICE SENSITIVE	223.84KB	Share
SPL VIRALEZE registered in Vietnam with launch this week
01/12/21	PRICE SENSITIVE	213.23KB	Share
SPL AGM Results
30/11/21		212.4KB	Share
SPL AGM Chairman address and CEO presentation
30/11/21	PRICE SENSITIVE	9.34MB	Share
SPL Positive DEP phase 2 interim results in prostate cancer
25/11/21	PRICE SENSITIVE	325.01KB	Share
SPL Jobkeeper s323DB(1) notice
11/11/21		217.03KB	Share
SPL Starpharma to present at Bell Potter Healthcare Conference
09/11/21		6.06MB	Share
SPL Application for quotation of securities - SPL
01/11/21		26.23KB	Share
SPL Notice of Annual General Meeting/Proxy Form
29/10/21		2.04MB	Share
SPL Quarterly Cashflow and Activities Report
29/10/21	PRICE SENSITIVE	520.01KB	Share
SPL Starpharma to present DEP at US Drug Delivery Conference
28/10/21		207.37KB	Share
SPL VIRALEZE distribution and supply to Vietnam
26/10/21	PRICE SENSITIVE	223.97KB	Share
SPL Notification regarding unquoted securities - SPL
25/10/21		26.46KB	Share
SPL VIRALEZE ADMENTA agreement - supplementary information
12/10/21		203.32KB	Share
SPL VIRALEZE launch in ADMENTA Italia Group pharmacies in Italy
08/10/21	PRICE SENSITIVE	434.53KB	Share
SPL Change in Director's Interest Notice - J Fairley
01/10/21		191.8KB	Share
SPL Notification of cessation of securities - SPL
01/10/21		21.51KB	Share
SPL 2021 Annual General Meeting
01/10/21		194.43KB	Share
SPL US patent issued for DEP cabazitaxel nanoparticle
15/09/21		223.41KB	Share
SPL Application for quotation of securities - SPL
13/09/21		26.23KB	Share
SPL Change in Director's Interest Notice - Z Peach
31/08/21		170.47KB	Share
SPL Change in Director's Interest Notice - J Fairley
30/08/21		189.4KB	Share
SPL Change in Director's Interest Notice - R Thomas
27/08/21		171.95KB	Share
SPL Change in Director's Interest Notice - L Cheng
27/08/21		170.49KB	Share
SPL Appendix 4G - Corporate Governance Statement
26/08/21		401.05KB	Share
SPL Starpharma annual report and full year financial results
26/08/21	PRICE SENSITIVE	4.97MB	Share
SPL VIRALEZE Protects Against SARS-CoV-2 in Challenge Model
23/08/21	PRICE SENSITIVE	346.96KB	Share
SPL VIRALEZE well tolerated in multiple dose clinical study
17/08/21	PRICE SENSITIVE	218.14KB	Share
SPL Initial Director's Interest Notice
02/08/21		237.65KB	Share
SPL Quarterly Cashflow and Activities Report
30/07/21	PRICE SENSITIVE	458.77KB	Share
SPL Resignation of non-executive director
29/07/21		409.71KB	Share
SPL Lynda Cheng appointed as non-executive director
28/07/21		194.8KB	Share
SPL Starpharma to present DEP platform at CRS Annual Meeting
27/07/21		195.96KB	Share
SPL VIRALEZE SPL7013 virucidal against SARS-CoV-2 Delta variant
27/07/21	PRICE SENSITIVE	293.54KB	Share
SPL TGA infringement notices for alleged advertising
05/07/21		199.5KB	Share
SPL Change in substantial holding
02/07/21		6.44MB	Share
SPL Starpharma to present at Virtual Life Science Investor Forum
24/06/21		6.78MB	Share
SPL VIRALEZE UK Update
21/06/21	PRICE SENSITIVE	189.86KB	Share
SPL VIRALEZE SPL7013 virucidal against multiple COVID variants
18/06/21	PRICE SENSITIVE	489.28KB	Share
SPL VIRALEZE antiviral nasal spray registered for sale in India
11/06/21	PRICE SENSITIVE	271.42KB	Share
SPL VIRALEZE SPL7013 highly active in UK variant of coronavirus
01/06/21	PRICE SENSITIVE	506.94KB	Share
SPL VIRALEZE partners with Harlequins in the UK
11/05/21		851.24KB	Share
SPL VIRALEZE launches in Europe
06/05/21	PRICE SENSITIVE	218.14KB	Share
SPL Shareholder Newsletter
28/04/21		1.13MB	Share
SPL Quarterly Cashflow and Activities Report
27/04/21	PRICE SENSITIVE	296.53KB	Share
SPL Appendix 2A
09/04/21		300.37KB	Share
SPL VIRALEZE now launched by LloydsPharmacy in the UK
30/03/21		223.8KB	Share
SPL VIRALEZE to be launched with LloydsPharmacy in the UK
25/03/21	PRICE SENSITIVE	240.28KB	Share
SPL DEP HER2-lutetium outperforms in human breast cancer model
16/03/21	PRICE SENSITIVE	252.17KB	Share
SPL SPL7013 active against other pandemic coronaviruses
03/03/21		417.63KB	Share
SPL Interim Report and Half-Year Financial Results
25/02/21	PRICE SENSITIVE	1.36MB	Share
SPL VIRALEZE antiviral nasal spray registered in Europe
23/02/21	PRICE SENSITIVE	225.86KB	Share
SPL Starpharma signs DEP ADC Research Agreement with MSD
12/02/21	PRICE SENSITIVE	171.94KB	Share
SPL AZD0466 clinical DEP program global expansion
09/02/21	PRICE SENSITIVE	58.71KB	Share
SPL Change in substantial holding
03/02/21		5.18MB	Share
SPL Quarterly Cashflow and Activities Report
29/01/21	PRICE SENSITIVE	102.2KB	Share
SPL Appendix 2A
27/01/21		167.74KB	Share
SPL Change in substantial holding
18/01/21		188.68KB	Share
SPL Change in substantial holding
18/01/21		200.44KB	Share
SPL Change in substantial holding
24/12/20		84.03KB	Share
SPL VIRALEZE COVID-19 nasal spray study to commence in January
22/12/20	PRICE SENSITIVE	70.54KB	Share
SPL Change in substantial holding
22/12/20		467.34KB	Share
SPL VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
10/12/20	PRICE SENSITIVE	112.23KB	Share
SPL Change in Director's Interest Notice - J Fairley
24/11/20		75.25KB	Share
SPL Appendix 3G
24/11/20		131.6KB	Share
SPL Retirement of non-executive director Richard Hazleton
20/11/20		209.68KB	Share
SPL 2020 AGM Results
20/11/20		84KB	Share
SPL AGM Chairman address and CEO presentation
20/11/20	PRICE SENSITIVE	3.8MB	Share
SPL SPL7013 shows potent antiviral activity in RSV
19/11/20	PRICE SENSITIVE	94.96KB	Share
SPL Appendix 3G
13/11/20		134.12KB	Share
SPL Change in Director's Interest Notice - R Thomas
04/11/20		75.62KB	Share
SPL Change in Director's Interest Notice - J Fairley
04/11/20		166.14KB	Share
SPL Change in Director's Interest Notice - Peter Turvey
04/11/20		74.7KB	Share
SPL Appendix 2A
04/11/20		169.13KB	Share
SPL Appendix 2A
30/10/20		173KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 13.0¢		Change 0.000(0.00%)		Mkt cap ! $54.36M

Open	High	Low	Value	Volume
13.5¢	13.5¢	13.0¢	$30.60K	232.5K

Buyers (Bids)

No.	Vol.	Price($)
1	458760	13.0¢

Sellers (Offers)

Price($)	Vol.	No.
13.5¢	87374	5

View Market Depth

No.	Vol.	Price($)
1	458760	0.130
2	51308	0.125
1	43350	0.115
2	9099	0.110
2	86433	0.105

Price($)	Vol.	No.
0.135	87374	5
0.140	162743	4
0.145	71840	7
0.150	175000	3
0.155	108518	3

Last trade - 15.09pm 05/09/2025 (20 minute delay)

SPL (ASX) Chart

STARPHARMA HOLDINGS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories